BBWI vs CL vs TEVA Stock Comparison

Bath & Body Works, Colgate Palmolive and Teva Pharmaceutical Industries Prices as of Nov 13, 2026 Peers: Industry group
BBWI Bath & Body Works, Inc.
$21.38 +12.9% 1M -2.8% 1Y
Market cap
$4.21B
P/E
4.1x
Revenue (TTM)
$11.78B
Div. yield
-0.07%
Personal Care Products Consumer Staples
6 wins
CL Colgate Palmolive Co
$99.67 +7.4% 1M +26.5% 1Y
Market cap
$80.85B
P/E
39.4x
Revenue (TTM)
$21.28B
Div. yield
0.02%
Personal Care Products Consumer Staples
3 wins

Head to Head

11 decided of 12

Bath & Body Works leads on 6 of the 12 questions below (Bath & Body Works 6, Colgate Palmolive 3, Teva Pharmaceutical Industries 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionBBWICLTEVALeader
Larger companyMarket capitalisation $4.21B $80.85B $50.31B CL
Cheaper on earningsLower P/E, profitable companies only 4.1x 39.4x 99.4x BBWI
Cheaper on forward earningsLower price / next fiscal year consensus EPS 7.6x 26.2x 22.7x BBWI
Faster revenue growthRevenue growth, trailing twelve months +92.8% +5.9% +2.7% BBWI
More profitableNet margin, trailing twelve months 8.7% 9.6% 2.9% CL
Better return on capitalReturn on invested capital 68.8% 27.6% 5.9% BBWI
Less leveragedLower net debt / EBITDA 1.3x 1.6x 5.2x BBWI
Higher dividend yieldTrailing dividend yield -0.07% 0.02% 0.00% –
Better 1-year returnPrice return, last 12 months -2.8% +26.5% +74.4% TEVA
Better 5-year returnAnnualised price return, 5 years -22.2%/yr +5.0%/yr +36.2%/yr TEVA
Less volatileAnnualised volatility, 1 year 62.1% 23.5% 33.4% CL
Higher overall scoreMean of the five percentile scores vs peers 69/100 61/100 62/100 BBWI

Percentile Scorecard

BBWICLTEVA

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisBBWICLTEVA
Valuation 98 #2 of 55 54 #26 of 55 82 #120 of 660
Growth 69 #17 of 52 61 #21 of 52 68 #201 of 619
Profitability 94 #4 of 50 98 #2 of 50 86 #87 of 595
Financial Health 45 #33 of 59 43 #34 of 59 11 #608 of 683
Shareholder Returns 39 #20 of 32 52 #16 of 32 –
Overall 69 61 62
  • BBWI ranked among 60 companies in Household and Personal Products
  • CL ranked among 60 companies in Household and Personal Products
  • TEVA ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodBBWICLTEVASPY
1 month +12.9%+7.4%+9.3% -2.0%
3 months +10.1%+8.4%+21.1% -2.8%
6 months +25.1%+13.1%+29.9% +2.0%
Year to date +6.5%+26.1%+42.7% +10.6%
1 year -2.8%+26.5%+74.4% +12.2%
3 years -32.1%+30.0%+399.9% +68.1%
3 years, per year -12.1%+9.2%+71.0% +18.9%
5 years -71.4%+27.7%+368.3% +61.4%
5 years, per year -22.2%+5.0%+36.2% +10.1%
10 years -61.8%+47.8%+9.6% +248.5%
10 years, per year -9.2%+4.0%+0.9% +13.3%

Risk

MeasureBBWICLTEVASPY
Volatility, 1Y 62.1%23.5%33.4% 13.6%
Downside volatility, 1Y 64.1%21.8%27.5% 13.9%
Beta vs S&P 500, 1Y 1.35-0.100.59 1.00
Return / volatility, 1Y -0.041.132.23 0.90
Max drawdown, 5Y -81.1%-31.1%-43.7% -25.4%
From 52-week high -13.3%0.0%0.0% -3.2%
52-week high $24.67$99.67$44.54 $779.14
52-week low $14.85$76.11$24.21 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleBBWICLTEVA
P/E now vs peer median 4.5xmedian 21.1x 38.7xmedian 21.1x 102.6xmedian 17.0x
P/S now vs peer median 0.4xmedian 2.2x 3.7xmedian 2.2x 3.0xmedian 8.4x
EV/EBITDA now vs peer median 3.3xmedian 14.0x 22.5xmedian 14.0x 26.7xmedian 14.6x
P/FCF now vs peer median 3.0xmedian 17.3x 20.9xmedian 17.3x 42.0xmedian 19.0x
P/B now vs peer median -4.1xmedian 1.9x 123.8xmedian 1.9x 6.5xmedian 2.0x
PEG now vs peer median 1.59median 0.87 3.79median 0.87 3.39median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsBBWICLTEVA
Revenue $11.78B $21.28B $17.23B
Gross profit $5.13B $12.90B $9.22B
Operating income $1.73B $3.16B $1.44B
Net income $1.03B $2.17B $508.00M
Free cash flow $1.46B $3.79B $1.24B
R&D – – $1.76B
EPS (diluted) $5.08 $2.57 $0.43
Cash & equivalents $794.00M $1.53B $4.09B
Total debt $3.61B $7.72B $16.72B
Shares (diluted) 202.00M 799.70M 1.18B
Enterprise value $2.00B $75.33B $35.28B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricBBWICLTEVA
P/E 4.5x 38.7x 102.6x
P/FCF 3.0x 20.9x 42.0x
P/Operating cash flow 3.1x 18.1x 29.4x
P/S 0.4x 3.7x 3.0x
P/B -4.1x 123.8x 6.5x
P/Tangible book -3.5x -95.2x 11.1x
EV/EBITDA 3.3x 22.5x 26.7x
EV/EBIT 4.1x 27.0x 45.0x
EV/Revenue 0.6x 4.0x 3.7x
EV/FCF 4.9x 22.5x 52.3x
EV/Operating cash flow 5.2x 19.6x 36.5x
PEG (3Y EPS CAGR) 1.59 3.79 3.39

Growth

14 metrics
MetricBBWICLTEVA
Revenue growth (1Y) 92.8% 5.9% 2.7%
Revenue CAGR (3Y) 24.0% 3.6% 4.1%
Gross profit growth (1Y) -1.8% 6.7% 9.7%
Gross profit CAGR (3Y) -0.2% 5.6% 9.6%
Operating income growth (1Y) -6.3% -26.1% -21.5%
Operating income CAGR (3Y) -3.8% 0.5% 46.4%
Net income growth (1Y) -4.3% -28.6% -23.3%
Net income CAGR (3Y) -1.4% 7.7% 30.3%
EPS growth (1Y) 0.0% -28.5% -30.1%
EPS CAGR (3Y) 2.8% 10.2% 30.2%
Operating cash flow growth (1Y) 39.6% 8.8% 66.0%
Operating cash flow CAGR (3Y) 2.2% 10.0% 15.2%
Free cash flow growth (1Y) 37.2% 10.0% 113.8%
Free cash flow CAGR (3Y) 2.6% 14.1% 26.7%

Profitability

14 metrics
MetricBBWICLTEVA
Gross margin 43.5% 60.6% 53.5%
EBITDA margin 18.4% 17.9% 14.0%
Operating margin 14.7% 14.8% 8.3%
Pretax margin 11.2% 13.9% 2.1%
Net margin 8.7% 9.6% 2.9%
FCF margin 12.4% 17.8% 7.2%
Operating cash flow margin 11.7% 20.5% 10.3%
Return on equity – 360.5% 6.5%
Return on assets 29.5% 13.0% 1.3%
Return on invested capital 68.8% 27.6% 5.9%
Return on capital employed 51.7% 31.2% 5.9%
Asset turnover 2.3x 1.3x 0.4x
Cash conversion (OCF / net income) 1.3x 2.0x 3.5x
Stock comp / revenue 0.4% 0.8% 1.0%

Financial Health

11 metrics
MetricBBWICLTEVA
Debt / assets 70.1% 46.1% 41.8%
Debt / equity -3.4x 12.1x 2.1x
Net debt / EBITDA 1.3x 1.6x 5.2x
Debt / FCF 2.5x 2.0x 13.5x
Liabilities / assets 120.5% 96.2% 80.1%
Equity / assets -20.5% 3.8% 19.9%
Interest coverage 22.8x 12.6x –
Current ratio 1.2x 1.0x 0.9x
Quick ratio 0.6x 0.5x 0.5x
Cash ratio 0.5x 0.2x 0.3x
Altman Z-score 3.56 7.12 1.02

Shareholder Returns

7 metrics
MetricBBWICLTEVA
Dividend yield 3.7% 2.1% –
Net buyback yield -6.6% 1.4% –
Shareholder yield -2.8% 3.6% 0.0%
Payout ratio (earnings) 28.1% 84.2% –
Payout ratio (FCF) 19.8% 48.3% –
Dividend growth (1Y) 5.9% 0.9% –
Dividend CAGR (3Y) 3.9% 1.9% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusBBWICLTEVA
Forward P/E 7.6xFY2026 26.2xFY2026 22.7xFY2026
EPS, next fiscal year $2.81FY2026 $3.81FY2026 $1.96FY2026
EPS growth, next FY -12.5%FY2026 +3.3%FY2026 -33.1%FY2026
EPS growth, the year after -5.3% +10.5% +65.3%
Revenue, next fiscal year $7.36BFY2026 $22.41BFY2026 $15.89BFY2026
Revenue growth, next FY +1.0%FY2026 +10.0%FY2026 -8.0%FY2026
Revenue growth, the year after +0.4% +1.3% +16.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersBBWICLTEVA
Held by institutions 95.8% 83.8% 62.7%
Institutions holding 465 2,019 672
Change in shares held, QoQ +1.6% 0.0% +8.6%
Institutions buying 245 921 359
Institutions selling 171 722 192
Buyers to sellers 1.43 1.28 1.87

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

BBWICLTEVA
BBWI 1.00 0.19 0.04
CL 0.19 1.00 0.12
TEVA 0.04 0.12 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, BBWI, CL and TEVA?

Colgate Palmolive (CL) is the largest by market capitalisation: Bath & Body Works (BBWI) $4.21B, Colgate Palmolive (CL) $80.85B, Teva Pharmaceutical Industries (TEVA) $50.31B.

Which stock is cheaper, BBWI, CL and TEVA?

Bath & Body Works (BBWI) trades on the lowest price-to-earnings ratio (Bath & Body Works (BBWI) 4.1x, Colgate Palmolive (CL) 39.4x, Teva Pharmaceutical Industries (TEVA) 99.4x). On next year's consensus earnings, Bath & Body Works (BBWI) is cheapest (Bath & Body Works (BBWI) 7.6x, Colgate Palmolive (CL) 26.2x, Teva Pharmaceutical Industries (TEVA) 22.7x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Bath & Body Works (BBWI) grew revenue fastest over the trailing twelve months: Bath & Body Works (BBWI) +92.8%, Colgate Palmolive (CL) +5.9%, Teva Pharmaceutical Industries (TEVA) +2.7%.

Which company is more profitable?

Colgate Palmolive (CL) has the highest net margin (Bath & Body Works (BBWI) 8.7%, Colgate Palmolive (CL) 9.6%, Teva Pharmaceutical Industries (TEVA) 2.9%). On return on invested capital, Bath & Body Works (BBWI) leads (Bath & Body Works (BBWI) 68.8%, Colgate Palmolive (CL) 27.6%, Teva Pharmaceutical Industries (TEVA) 5.9%).

Which stock has performed better?

Over the past year Teva Pharmaceutical Industries (TEVA) returned the most: Bath & Body Works (BBWI) -2.8%, Colgate Palmolive (CL) +26.5%, Teva Pharmaceutical Industries (TEVA) +74.4%. Over five years, Teva Pharmaceutical Industries (TEVA) compounded fastest (Bath & Body Works (BBWI) -22.2%/yr, Colgate Palmolive (CL) +5.0%/yr, Teva Pharmaceutical Industries (TEVA) +36.2%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Bath & Body Works (BBWI) -0.07%, Colgate Palmolive (CL) 0.02%, Teva Pharmaceutical Industries (TEVA) 0.00%. Bath & Body Works (BBWI) and Teva Pharmaceutical Industries (TEVA) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Colgate Palmolive (CL) has been the steadiest (Bath & Body Works (BBWI) 62.1%, Colgate Palmolive (CL) 23.5%, Teva Pharmaceutical Industries (TEVA) 33.4%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, BBWI, CL and TEVA?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Bath & Body Works (BBWI) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.